<code id='5F4146190D'></code><style id='5F4146190D'></style>
    • <acronym id='5F4146190D'></acronym>
      <center id='5F4146190D'><center id='5F4146190D'><tfoot id='5F4146190D'></tfoot></center><abbr id='5F4146190D'><dir id='5F4146190D'><tfoot id='5F4146190D'></tfoot><noframes id='5F4146190D'>

    • <optgroup id='5F4146190D'><strike id='5F4146190D'><sup id='5F4146190D'></sup></strike><code id='5F4146190D'></code></optgroup>
        1. <b id='5F4146190D'><label id='5F4146190D'><select id='5F4146190D'><dt id='5F4146190D'><span id='5F4146190D'></span></dt></select></label></b><u id='5F4146190D'></u>
          <i id='5F4146190D'><strike id='5F4146190D'><tt id='5F4146190D'><pre id='5F4146190D'></pre></tt></strike></i>

          focus

          focus

          author:explore    Page View:29

          This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

          Hello, friends! I’m in San Francisco for the STAT Breakthrough Summit. Later today, I’ll be “fireside chatting” with Cytokinetics CEO Robert Blum. It’s not too late to join us virtually. Check out details here.

          advertisement

          It’s a travel-shortened week for me, so in this newsletter, I decided to dive deep into PDS Biotech and its experimental drug for head and neck cancer. PDS is what I’d call a biotech cult stock.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          RSV shot was 90% effective at preventing hospitalizations in kids
          RSV shot was 90% effective at preventing hospitalizations in kids

          Thiselectronmicroscopeimageshowshumanrespiratorysyncytialvirus(RSV)virions,colorizedblue,andanti-RSV

          read more
          What does generative AI mean for health care? We asked experts
          What does generative AI mean for health care? We asked experts

          MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

          read more

          First medicine developed to treat MASH expected to be approved soon

          MadrigalCEOBillSiboldsaysthecompanyis"interestedinthepatientswhoaremostinneed."MadrigalPharmaceutica